Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin in Type 2 Diabetes with Chronic Heart Failure
NCT05742230Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Apr 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of henagliflozin in type 2 diabetes mellitus (T2DM) and heart failure (HF) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score at 12 weeks. Started Apr 2023; status: recruiting.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure (HF)
Beyond the preview
Go deeper on NCT05742230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05742230.